Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.40 |
| ▸ | DRD3 | P35462 | 10/20 | 0.40 |
| ▸ | DRD4 | P21917 | 9/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3259421 | 0.99 | DRD2 (0.41) | DRD2DRD3DRD4PDE4BHTR1A | |
| SCHEMBL3079445 | 0.96 | DRD2 (0.38) | DRD2DRD3DRD4PDE4BHTR1A | |
| SCHEMBL3065555 | 0.95 | DRD2 (0.39) | DRD2DRD3DRD4PDE4BHTR1A | |
| SCHEMBL3417423 | 0.93 | DRD2 (0.42) | DRD2DRD3DRD4PDE4B | |
| SCHEMBL3416611 | 0.92 | REN (0.43) | DRD2DRD3DRD4 | |
| SCHEMBL3080376 | 0.92 | DRD2 (0.42) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL3420106 | 0.91 | DRD2 (0.39) | DRD2DRD3DRD4PDE4B | |
| SCHEMBL3080549 | 0.91 | DRD2 (0.38) | DRD2DRD3DRD4PDE4BHTR1A | |
| SCHEMBL3084947 | 0.91 | DRD2 (0.43) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL3065748 | 0.90 | DRD2 (0.39) | DRD2DRD3DRD4PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | DRD2 425/4885DRD3 615/4885DRD4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.